Central line acquired infection describes a serious complication that occurs when pathogens colonize a central venous catheter, often due to breaks in sterile technique during insertion or ongoing care. These infections are a major concern in hospitals and intensive care units because they can transform a lifesaving access route into a direct portal for bacteria or fungi into the bloodstream. Prompt recognition and targeted management are essential to reduce the risk of sepsis, prolonged hospitalization, and death. Understanding the mechanisms, risk factors, and preventive strategies is critical for clinicians managing patients with these devices.

The development of a central line acquired infection carries significant morbidity and places a substantial burden on healthcare systems worldwide. The pathogens responsible are frequently resistant bacteria, making treatment particularly challenging and necessitating prolonged courses of intravenous antibiotics. The infection can remain localized at the catheter site or progress rapidly to cause bacteremia, affecting multiple organs. This underscores the importance of vigilance, early detection, and adherence to evidence-based protocols to mitigate these dangers.

Primary Risk Factors and Pathogenesis
The likelihood of developing a central line acquired infection increases with several modifiable and non-modifiable factors. Patient-related factors such as immunosuppression, severe underlying illness, and prolonged hospitalization create a susceptible baseline that favors microbial invasion. Device-related factors, including the duration of catheterization and the number of lumens, further elevate the risk by providing longer exposure to potential contamination.

Pathogenesis typically occurs through several distinct routes, with the most common being the migration of skin flora along the tract of the catheter toward the tip. Organisms can also be introduced during the manipulation of the catheter hub or infusion sets, highlighting the importance of meticulous aseptic technique. Once microbes reach the catheter tip, they form a protective biofilm that shields them from host immune defenses and many antibiotics, allowing the infection to persist and disseminate.
Microbial Culprits and Virulence

The microbiology of central line acquired infection varies by care setting and patient population, but certain organisms predominate. Coagulase-negative staphylococci, particularly Staphylococcus epidermidis, are frequently isolated due to their ability to adhere readily to synthetic materials and form biofilms. These skin commensals are often implicated in early-onset infections related to recent catheter insertion.
More concerning pathogens include Staphylococcus aureus, including methicillin-resistant strains (MRSA), and gram-negative bacilli such as Pseudomonas aeruginosa and Escherichia coli. Candida species are also significant culprits, especially in patients receiving broad-spectrum antibiotics or parenteral nutrition. The virulence of these organisms, combined with the protected environment of the biofilm, makes eradication difficult without removing the device.
Clinical Recognition and Diagnostic Approach

Recognizing a central line acquired infection requires a high index of suspicion, particularly in patients with an indwelling catheter who develop fever, chills, or unexplained hypotension. Local signs of inflammation, such as erythema, warmth, or purulent drainage at the insertion site, are important clues. However, infections can also be occult, presenting only with systemic signs of sepsis without obvious local inflammation.
The diagnostic workup hinges on both blood cultures and targeted catheter tip cultures to establish the identity of the pathogen. Drawing blood cultures from both the central line and a peripheral vein allows for comparison, with a positive line-to-peripheral differential time-to-positivity supporting the diagnosis. Molecular methods and rapid diagnostic tests are increasingly used to expedite identification and guide initial therapy while awaiting final culture results.
Microbiological Confirmation and Biomarkers

Obtaining adequate samples for culture is essential, as empiric treatment without confirmation can lead to inappropriate therapy and resistance development. The focus should be on quantitative cultures or semi-quantitative roll-plate methods, which offer greater diagnostic accuracy than simple routine culture. These techniques help distinguish true colonization from contamination and provide critical data on the microbial burden.
While biomarkers such as procalcitonin and C-reactive蛋白 can support the suspicion of bacterial infection and monitor response to therapy, they should not replace microbiological confirmation. These tools are most useful in conjunction with clinical assessment and culture data. They help clinicians interpret the significance of colonization and avoid unnecessary antibiotic escalation in asymptomatic carriers.




















Prevention Strategies and Management Principles
Preventing central line acquired infection begins with strict adherence to insertion and maintenance bundles that encompass hand hygiene, maximal sterile barriers, and the use of chlorhexidine-based antiseptics. Careful selection of the insertion site, favoring the femoral vein in specific scenarios despite its higher infection risk, and diligent daily assessment of the ongoing need for the catheter are fundamental components of care.
When infection is suspected, the management strategy—whether to remove the catheter or retain it—depends on the clinical syndrome and the causative organism. For uncomplicated bacteremia caused by coagulase-negative staphylococci, antibiotic therapy alone may suffice if the catheter is not required. In contrast, infections caused by S aureus, Pseudomonas, or fungi generally necessitate catheter removal to achieve source control and ensure successful treatment.
Antimicrobial Therapy and Duration
The selection of antimicrobial agents is guided by culture and susceptibility results, local antibiograms, the severity of illness, and the presence of complications such as endocarditis or osteomyelitis. Empiric therapy should cover staphylococci, enterococci, and gram-negative rods in critically ill patients until definitive data are available. The duration of therapy is typically prolonged, often ranging from two to six weeks, depending on the pathogen and the presence of complications.
For biofilm-associated infections, antibiotics alone are frequently inadequate because the matrix protects microbes from drug penetration and immune clearance. This biological reality necessitates the removal of the infected device as a cornerstone of therapy. Multidisciplinary collaboration involving intensivists, infectious disease specialists, and antimicrobial stewardship teams is often required to optimize outcomes and minimize the emergence of resistance.
Looking ahead, ongoing improvements in catheter design, such as antimicrobial-coated surfaces and advanced lock solutions, hold promise for further reducing the incidence of these difficult-to-treat infections. Continued education and protocol-driven care remain the best defenses against this persistent threat to patient safety.